Pemigatinib can cause retinal pigment epithelial detachment. Perform ophthalmological examination including optical coherence tomography prior to initiation of therapy, every 2 months for the first 6 months of treatment and every 3 months thereafter, and urgently at any time for visual symptoms.
- TRADE NAMES: INCB 54828-101; INCB054828; Pemazyre (Incyte)
- INDICATIONS: Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
- CLASS: Fibroblast growth factor receptor inhibitor, Kinase inhibitor
- HALF-LIFE: 15.4 hours
- FDA APPROVAL DATE: 04/17/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers, CYP3A inhibitors, Itraconazole, Rifampin - PREGNANCY: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to the fetus and use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of pemigatinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/07/2026
